Back | Next |
home / stock / avxl / avxl message board
Subject | By | Source | When |
---|---|---|---|
Their larger AD clinical program not withstanding, it | frrol | investorshub | 07/17/2024 1:03:44 PM |
Strumbles -- a stumbles/troubles mashup. Good neologism. | boi568 | investorshub | 07/17/2024 1:01:19 PM |
The drug may be harmless, but who would | boi568 | investorshub | 07/17/2024 12:59:18 PM |
It doesn't take much dot connecting between the | boi568 | investorshub | 07/17/2024 12:57:25 PM |
Let's hope they don't throw baby (us) out | Thehubby | investorshub | 07/17/2024 12:51:57 PM |
Cassava's strumbles show the importance of strong corporate | frrol | investorshub | 07/17/2024 12:39:38 PM |
ABBY-NORMAL...quiet ...? | nidan7500 | investorshub | 07/17/2024 12:34:34 PM |
Here's the link -34% in PM | Doc328 | investorshub | 07/17/2024 12:34:18 PM |
Remi gone. Sava dead. | BAR123 | investorshub | 07/17/2024 12:18:49 PM |
But Im confident youd prefer more lawsuits due | Graniteguy | investorshub | 07/17/2024 12:16:36 PM |
Yes the original move by Anavex lawyers to | Investor2014 | investorshub | 07/17/2024 11:57:56 AM |
It's the market maker offsetting and stopping the | sab63090 | investorshub | 07/17/2024 9:52:18 AM |
Dupe message DELETED | sab63090 | investorshub | 07/17/2024 9:46:07 AM |
I thought I read that Kaufmann was presenting | sab63090 | investorshub | 07/17/2024 9:46:06 AM |
Thank you for your update and comments ! | sab63090 | investorshub | 07/17/2024 9:35:04 AM |
Hi Leo well that wouldn't quite be | k9uwa | investorshub | 07/17/2024 5:23:15 AM |
I wouldnt be surprised, there was a small | Rubyred77 | investorshub | 07/17/2024 4:17:23 AM |
HI Tom One more possibility. One of our | k9uwa | investorshub | 07/17/2024 3:55:46 AM |
Guzzi62, I understand what you are saying. They | vg_future | investorshub | 07/17/2024 3:31:18 AM |
Lots of skunks and poops today.🙂 | 123tom | investorshub | 07/17/2024 3:22:00 AM |
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events Clinical benefit of blarcamesine consistently observed for both 30 mg and 50 mg treatment groups ...
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...